• Conference call and webcast to be held
tomorrow, January 2, at 8:30am ET (5:30am PT)
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that it will host a conference call to discuss topline data from
the PACIFIC Study, a Phase 1b/2a clinical trial evaluating
bexicaserin (LP352) in participants with a broad range of
Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin is
a potentially best-in-class, oral, novel, 5-HT2C receptor
superagonist with no observed impact on 5-HT2B and 5-HT2A receptor
subtypes.
Conference Call and Webcast Details
Longboard will host a conference call tomorrow, January 2, at
8:30am ET. Stockholders and other interested parties may
participate in the call by following the instructions below. The
live webcast can be accessed on the Events & Presentations
portion of the investor page of Longboard’s website at
https://ir.longboardpharma.com. A replay will be available on
Longboard’s website shortly after completion of the event and will
be archived for up to 30 days.
Participant Webcast Link:
https://edge.media-server.com/mmc/p/sqg9yxpf
Participant Call Link:
https://register.vevent.com/register/BIb92b4a3dd66f44fdbc3fcd202fca9caf
1.
Click on the call link and
complete the online registration form.
2.
Upon registering you will receive
the dial-in info and a unique PIN to join the call as well as an
email confirmation with the details.
3.
Select a method for joining the
call;
i. Dial-In: A dial in number and
unique PIN are displayed to connect directly from your phone.
ii. Call Me: Enter your phone
number and click “Call Me” for an immediate callback from the
system. The call will come from a U.S. number.
ABOUT BEXICASERIN (LP352)
Bexicaserin is an oral, centrally acting, 5-HT2C superagonist in
development for the potential treatment of seizures associated with
DEEs such as Lennox-Gastaut syndrome, Dravet syndrome,
SCN2A-related epilepsies, CDKL5 deficiency disorder, and other
epileptic disorders. Bexicaserin is designed to modulate GABA and,
as a result, suppress the central hyperexcitability that is
characteristic of seizures. Bexicaserin has novel chemistry and
attributes, and was designed to be highly specific and selective
for the 5-HT2C receptor subtype, giving it the potential to reduce
seizures in patients with DEEs while overcoming the known or
perceived safety limitations of available drugs in the 5-HT2
class.
ABOUT THE PACIFIC STUDY
The PACIFIC Study is a Phase 1b/2a double-blind,
placebo-controlled clinical trial to assess the safety,
tolerability, efficacy and pharmacokinetics of bexicaserin (LP352)
in 52 participants between the ages of 12 and 65 years old at 34
sites across the U.S. and Australia. Following a 5-week screening
period and baseline evaluations, study participants initiated a
dose titration over a 15-day period and subsequently continued on
the highest tolerated dose throughout the maintenance period of 60
days. Following the maintenance period, participants were then
titrated down and eligible participants were given the opportunity
to enroll in a 52-week open-label extension program. The primary
efficacy measure is median percent change from baseline in
countable motor seizure frequency over the 75-day treatment
period.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard is evaluating bexicaserin (LP352), an oral,
centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor
superagonist with no observed impact on 5-HT2B and 5-HT2A receptor
subtypes. Bexicaserin is currently in a Phase 1b/2a clinical trial,
the PACIFIC Study, evaluating participants ages 12 to 65 years old
with a broad range of Developmental and Epileptic Encephalopathies
(DEEs), including Dravet syndrome, Lennox-Gastaut syndrome and
other DEEs. Longboard is also evaluating LP659, an oral, centrally
acting, next-generation sphingosine-1-phosphate (S1P) receptor
subtypes 1 and 5 modulator, which is in development for the
potential treatment of rare neuroinflammatory conditions in a Phase
1 single-ascending dose (SAD) clinical trial in healthy
volunteers.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. In
some cases, you can identify forward-looking statements by words
such as “to be held”, “focused on”, “will”, “potential”, “may”,
“after”, “emerging”, “opportunity”, “expected”, “designed to”,
“working to”, or the negative, plural or other tenses of these
words or other comparable language, and they include, without
limitation, statements about the following: Longboard’s planned
conference call and webcast; bexicaserin (LP352), including its
potential to be best-in-class, its potential to treat seizures
associated with a broad range of DEEs, and its selectivity, design,
chemistry, and attributes; and Longboard’s clinical and preclinical
programs and product candidates, ability to develop product
candidates and deliver medicines, and focus. For such statements,
Longboard claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Longboard’s expectations. Factors that could cause
actual results to differ materially from those stated or implied by
Longboard’s forward-looking statements include, but are not limited
to, the following: topline data may not accurately reflect the
complete results of a particular study or trial and remain subject
to audit, and final data may differ materially from topline data;
PACIFIC Study participants’ diagnoses are as of time of screening
and are subject to change; risks related to Longboard’s limited
operating history, financial position and need for additional
capital; Longboard will need additional managerial and financial
resources to advance all of its programs, and you and others may
not agree with the manner Longboard allocates its resources; risks
related to the development and commercialization of Longboard’s
product candidates; Longboard’s product candidates are in the early
phases of a lengthy research and development process, the timing,
manner and outcome of research, development and regulatory review
is uncertain, and Longboard’s product candidates may not advance in
research or development or be approved for marketing; enrolling
participants in Longboard’s ongoing and intended clinical trials is
competitive and challenging; nonclinical and clinical data is
voluminous and detailed, and regulatory agencies may interpret or
weigh the importance of data differently and reach different
conclusions than Longboard or others, request additional
information, have additional recommendations or change their
guidance or requirements before or after approval; results of
clinical trials and other studies are subject to different
interpretations and may not be predictive of future results;
macroeconomic events stemming from the COVID-19 pandemic or
evolving geopolitical developments such as the conflicts in Ukraine
and the Middle East, including but not limited to the impact on
Longboard’s clinical trials and operations, the operations of
Longboard’s suppliers, partners, collaborators, and licensees, and
capital markets, which in each case remains uncertain; risks
related to unexpected or unfavorable new data; risks related to
principal stockholders or management selling some or all of their
stock; risks related to relying on licenses or collaborative
arrangements; other risks related to Longboard’s dependence on
third parties; competition; product liability or other litigation
or disagreements with others; government and third-party payor
actions, including relating to reimbursement and pricing; risks
related to regulatory compliance; and risks related to Longboard’s
and third parties’ intellectual property rights. Additional factors
that could cause actual results to differ materially from those
stated or implied by Longboard’s forward-looking statements are
disclosed in Longboard’s filings with the Securities and Exchange
Commission (SEC). These forward-looking statements represent
Longboard’s judgment as of the time of this release. Longboard
disclaims any intent or obligation to update these forward-looking
statements, other than as may be required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240101532190/en/
Megan E. Knight Head of Investor Relations
IR@longboardpharma.com 858.789.9283
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
Von Mai 2023 bis Mai 2024